CHF has been engaged with the development of an electronic health record and system since its inception, and our submission is drawn from submissions into previous inquiries into the Personally Controlled Electronic Health Record (PCEHR) and similar issues, as well as the experiences of our consumer representatives on key committees.
The major implication of these results for health policymakers is that defenders of traditional “silos” of medicine need to rethink what ought to be considered traditional roles for GPs and pharmacists. Moreover, if pharmacists are going to assume a greater role in the provision of primary care services, then the industry is going to have to think through what training and accommodation will be necessary to give consumers the confidence that these services do not compromise the quality they have come to expect from GPs.
Abstract: CHF's submission to the RACGP's Vision for a Sustainable Health System Discussion Paper.
The Consumers Health Forum of Australia (CHF) is pleased to provide a submission to the Issues Paper for the Post-Market Review of the Life-Saving Drugs Programme (the Issues Paper). Before going into the content of our views, we want to express our deep concerns with the limitations the Review has given to stakeholders to comment on the Issues Paper.
This is an initial analysis of the Federal Health Budget from the Consumers Health Forum of Australia (CHF). There is further detail in the Budget papers that require further appraisal before CHF takes a view on these aspects. We are preparing a more detailed analysis based on further briefings and consultations.
PHNs... Will they be good for our health?
This submission into the Availability of new, innovative and specialist cancer drugs in Australia draws on the experiences of our members and consumer representatives in assessing the availability and effectiveness of medicines in Australia, and in particular the operation of the Pharmaceutical Benefits Advisory Committee (PBAC) and the Pharmaceutical Benefits Scheme (PBS).
The definitive goal of this review of the regulatory framework should be the safety and quality of complementary medicines in Australia. Any new framework must carefully balance the risk to consumer safety and consumer choice concerns.